CONTACT: Carol Hausner, Senior Director, Investor Relations and Corporate Communications of ImmunoGen
Under the terms of the license agreement between ImmunoGen
and SB, in addition to royalties, ImmunoGen
could receive milestone payments totaling more than $40 million.
We look forward to receiving further payments as future milestones are achieved by ImmunoGen
and SB during the course of development.
Under Walter Blattler's guidance, ImmunoGen
has now taken five products from the bench to the clinic," observes Sayare.
McCarren's responsibilities will be assumed by Sayare and other members of the senior management team; ImmunoGen
has no immediate plans to replace McCarren.
Explaining the significance of resurfacing, Walter Blattler, ImmunoGen
Vice President, Research, notes that "Antibodies derived from mice are humanized so that they will appear human to the immune system.
These observations have led ImmunoGen
to use the Oncolysins following conventional therapies, to "mop up" residual disease which cannot be eliminated by conventional agents.
CONTACT: Mark Ratner, director of external communications for ImmunoGen
These negotiations have been initiated following a mutual decision by ImmunoGen
and Roussel-Uclaf of Romainville, France, that Roussel-Uclaf will relinquish the rights to Oncolysin B that it acquired several years ago under an agreement between the companies.
Following the completion of the study, ImmunoGen
plans to expand clinical trials of Oncolysin CD6 to assess its efficacy in the prevention of episodes of acute kidney transplant rejection.
He is a valuable addition to the ImmunoGen
team," states Donald J.